drugset / Trial / NCT00349180

Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

NCT00349180

Phase 3 Completed 156 enrolled Sanofi
RandomizedParallel-groupDouble-blindPrevention

Summary

This study is performed to confirm the optimal dose for THR (total hip replacement).

Timeline

Start
2006-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified 20 mg

Indications